Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol)

Overview

The purpose of this research study is to (1) provide access to fenfluramine for patients with intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety of fenfluramine.

Study Type

  • Study Type: Expanded Access

Detailed Description

The purpose of this research study is to (1) provide access to fenfluramine for patients with intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety of fenfluramine.

Interventions

  • Drug: Fenfluramine
    • The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 (fenfluramine hydrochloride) clinical trials.

Participating in This Clinical Trial

Inclusion Criteria

  • Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all available medications for seizures.

Gender Eligibility: All

Minimum Age: 2 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • University of California, Los Angeles
  • Provider of Information About this Clinical Study
    • Principal Investigator: Shaun Hussain, MD, Associate Professor – University of California, Los Angeles
  • Overall Contact(s)
    • Angela Martinez, 310-206-4037, angelamartinez@mednet.ucla.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.